On May 25, 2023, EF Hutton restated their coverage of Aravive (NASDAQ:ARAV) with a strong buy recommendation, according to Fintel.
The average one-year price target for Aravive as of May 11, 2023 is 13.26, with forecasts ranging from 10.10 to $18.90. This represents an increase of 802.04% from its latest reported closing price of 1.47.
Aravive’s projected annual revenue is $1 million, which is an 85.56% decrease, and its projected annual non-GAAP EPS is -1.37.
There are 59 funds or institutions reporting positions in Aravive, an increase of 5 owners or 9.26% in the last quarter. The average portfolio weight of all funds invested in ARAV is 0.04%, an increase of 258.00%. Total shares owned by institutions increased in the last three months by 22.48% to 18,695K shares. The put/call ratio of ARAV is 1.89, indicating a bearish outlook.
Some of the largest shareholders of Aravive include BVF, Artal Group, Baker Bros. Advisors, New Leaf Venture Partners, L.L.C., and Millennium Management.
Aravive is a clinical-stage oncology company based in Houston, Texas, developing transformative therapeutics to stop the progression of life-threatening diseases. Its lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth.
Aravive completed a Phase 1b trial of AVB-500 in platinum-resistant ovarian cancer and has initiated a registrational Phase 3 trial of AVB-500 at a dose of 15 mg/kg. Although the Phase 1b trial of AVB-500 in platinum-resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all five patients in the 15 mg/kg cohort experienced clinical benefit, with one complete response, two partial responses, and two stable diseases.
Key filings for Aravive can be found on Fintel.
Please note that the views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
